A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Cancer Res.

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

ISSN: 1078-0432

ISSN (Print): 1078-0432

Publication date (Electronic): Jan 1 2016

Volume: 22

Issue: 1

Affiliations

[1 ] Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy and University Paris-Sud, Villejuif, France. martin.schlumberger@gustaveroussy.fr.

[2 ] Department of Nuclear Medicine and Endocrine Oncology, Centrum Onkologii Instytut im. M. Sklodowskiei-Curie, Gliwice, Poland.

[3 ] Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.

[4 ] Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.

[5 ] Department of Medical, Surgical and Neurological Sciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy.

[6 ] Division of Endocrinology and Metabolism, Johns Hopkins Medical Institute, Baltimore, Maryland.

[7 ] Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

[8 ] NIHR Royal Marsden Hospital and Institute of Cancer Research BRC, London, UK.

[9 ] Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Australia.

[10 ] Division of Clinical Research, Seattle Cancer Care Alliance, Seattle, Washington.

[11 ] Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

[12 ] Department of Medical Oncology, The Ohio State University School of Medicine, Columbus, Ohio.

[13 ] Department of Otolaryngology-Head and Neck Surgery, University of Arkansas, Little Rock, Arkansas.

[14 ] Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

[15 ] Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

[16 ] Eisai, Andover, Massachusetts.

[17 ] Eisai Inc., Woodcliff Lake, New Jersey.

Article

Publisher Item ID: 1078-0432.CCR-15-1127

DOI: 10.1158/1078-0432.CCR-15-1127

PubMed ID: 26311725

SO-VID: c3c9878b-e8ce-4b1d-9a1d-7e9d861828b7

History

Data availability:

Comments

Comment on this article

scite_

Cited by 85

See all cited by